Walmart Drops on Weak Earnings; Merck Splits Analysts on Cancer Vaccine
Walmart shares sink after a disappointing earnings report while Merck's cancer vaccine news has Wall Street divided.
Walmart is taking a hit Thursday after posting earnings that failed to impress the market. When the world's largest retailer stumbles, you pay attention — this isn't a niche player. If consumer spending is slowing enough to drag Walmart's numbers down, that's a signal you don't ignore heading into the rest of the quarter.
Meanwhile, Merck is sitting at the center of a debate that actually matters. The pharma giant's cancer vaccine breakthrough sounds like a headline-grabbing win, but analysts aren't on the same page about what it means for the stock. Breakthroughs in oncology can take years to translate into revenue, and that gap between science and sales is exactly where bulls and bears fight it out.
Read more Warsh vs. Bessent: Fed Independence Under Fire on Rates →
These two stories tell you a lot about where the market's head is right now. On one side, you've got a defensive consumer staple cracking under pressure — that's a macro warning sign. On the other, you've got a biotech-style catalyst in a large-cap name, which is the kind of volatility traders chase. Neither situation is simple, and both deserve your full attention before you make a move.
Bottom line: don't just react to the headlines. Walmart's selloff could be a buying opportunity or a warning shot — you need to know which. And with Merck, figure out where you stand on the timeline between clinical promise and commercial payoff before you add or trim. Thursday is setting up as a tape that rewards discipline over impulse.
Continue reading at CNBC
